Century Therapeutics, Inc. (IPSC) Stock Forecast
IPSC analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.40 / 5 from 5 analysts
- Price target
- $4.75 average of analyst targets
- Upside to target
- +246.7% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.12
- 52-week range
- $0.46 – $2.94
IPSC analyst ratings
5 analystsNumber of analysts at each rating.
IPSC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IPSC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.12 | −$0.08 | −$0.32 | +65.6% | 4 |
| Current fiscal year (2026) | −$0.47 | −$0.52 | −$0.37 | −$0.03 | −1,309.9% | 3 |
| Next fiscal year (2027) | −$0.45 | −$0.55 | −$0.28 | −$0.47 | +3.6% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IPSC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
IPSC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IPSC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.12 | −$0.11 | −$0.11 | −$0.11 | −10.8% | 1 up · 1 down |
| Current fiscal year (2026) | −$0.46 | −$0.46 | −$0.45 | −$0.45 | −$0.47 | +1.5% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.46 | −$0.46 | −$0.45 | −$0.45 | −$0.45 | −1.6% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IPSC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IPSC beat in 8 of 12.
What analysts expect from IPSC
5 analysts cover Century Therapeutics; their consensus rating is buy (4.40 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.75, 246.7% above the latest close of $1.37. Analysts expect earnings of −$0.47 per share for 2026, −1,309.9% from a year earlier. For 2027 the average estimate is −$0.45 per share. Century Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: IPSC income statement, IPSC key metrics, IPSC chart. See the IPSC stock overview for the latest quote and news.
IPSC forecast FAQ
What is Century Therapeutics's price target?
The average analyst price target for Century Therapeutics is $4.75, 246.7% above the latest close of $1.37.
Is Century Therapeutics a buy, hold or sell?
Of 5 analysts covering Century Therapeutics, 3 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Century Therapeutics's EPS forecast?
Analysts forecast −$0.47 per share for 2026 (range −$0.52 to −$0.37); for 2027 the estimate is −$0.45.
When does Century Therapeutics report earnings?
Century Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.12.
Does Century Therapeutics usually beat earnings estimates?
Century Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.